Source: Pharmacy Times articles
Managing bispecific antibodies requires collaboration and meticulous protocols.
Read More
Recent Content
- A 30-Minute Infusion of Isatuximab Is Safe, Feasible in Patients with Newly Diagnosed Multiple Myeloma
- Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis
- PCMMD: A Novel Dataset of Plasma Cells to Support the Diagnosis of Multiple Myeloma
- International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma
- Navigating the Challenges of Bispecific Antibodies in Relapsed and Refractory Multiple Myeloma
- The association between the dietary inflammatory index and multiple myeloma: a case–control study
- Early intervention with daratumumab improves survival for patients with high-risk smouldering myeloma
- ‘Readily available biomarker’ can predict outcomes in multiple myeloma
- Rising from Ashes: Rediscovering Myself After Multiple Myeloma
- Ciltacabtagene Autoleucel Demonstrates Superior Progression-Free Survival in Patients With Relapsed, Refractory Multiple Myeloma